Biotectix, developer of coatings and conductive polymer materials for sensors and implantable medical devices, has acquired all major assets of Chameleon BioSurfaces based in Cambridge, UK, for an undisclosed amount.
Chameleon produces sophisticated polymer coatings that are applied on implantable medical equipment. The company’s proprietary technology uses polymer coatings that are electrically conductive for enhanced drug delivery, electrical performance, conformal coating and biocompatibility. Biotectix has expanded its intellectual property portfolio by acquiring numerous pending and issued US and worldwide patents of Chameleon.
Biotectix will now accommodate all material technologies of Chameleon at its facility located in Ann Arbor, Michigan. The company will also carry on the activities of pending and active projects for Chameleon clients.
The General Manager of Biotectix, James Arps, stated that the Chameleon technology is a perfect fit for Biotectix’s conductive thiophene-based polymer materials. The acquisition expands the options of materials available to the company’s co-development partners operating in the medical device industry.
The Chairman of Chameleon, Geoffrey Beanland, said that the company is proud about the advancements made in the electropolymerized coatings for life sustaining devices such as drug eluting stents. Biotectix expertise would further improve this technology, he added.
Source: http://www.biotectix.com